U.S. Markets closed

Bristol-Myers Squibb Company (BMY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
54.39+0.57 (+1.06%)
At close: 4:00PM EDT

54.67 0.28 (0.51%)
After hours: 6:24PM EDT

People also watch
MRKLLYABTPFEJNJ
Interactive chart
Previous Close53.82
Open53.89
Bid0.00 x
Ask0.00 x
Day's Range53.69 - 54.58
52 Week Range46.01 - 77.12
Volume8,493,124
Avg. Volume9,060,846
Market Cap89.6B
Beta0.97
PE Ratio (TTM)18.89
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.56 (2.90%)
Ex-Dividend Date2017-04-05
1y Target EstN/A
Trade prices are not sourced from all markets
  • Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer
    Zacks11 hours ago

    Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer

    Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).

  • Forbes14 hours ago

    Getting Struck Twice: Acquisitions And Spinouts In Biotech

    Biotech M&A deals are often driven by the buyer's interest in the lead asset in the biotech's portfolio. In order to capture the full value, spin-outs of the secondary assets following an acquisition can be solution. Several recent examples hare explored.

  • Market Realistyesterday

    Performance of Merck’s Diabetes Portfolio in 1Q17

    Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.